Monitoring of azathioprine/6-mercaptopurine treatment in children with IBD is not necessary

Inflammatory Bowel Diseases

Volumn 9, Issue 6, 2003, Pages 389-391

  Griffiths, Anne M ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

6 METHYLTHIOINOSINE; AZATHIOPRINE; DRUG METABOLITE; DRUG METABOLIZING ENZYME; IMMUNOMODULATING AGENT; MERCAPTOPURINE; MESALAZINE; NITROIMIDAZOLE; PLACEBO; PRODRUG; SALAZOSULFAPYRIDINE; STEROID; THIOGUANOSINE; THIOPURINE METHYLTRANSFERASE;

ARTICLE; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CHILD CARE; CHILD GROWTH; CLINICAL PRACTICE; CLINICAL TRIAL; CORRELATION ANALYSIS; CROHN DISEASE; DISEASE CONTROL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; DRUG RESPONSE; DRUG WITHDRAWAL; ENTERITIS; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LEUKOPENIA; LIVER TOXICITY; PATIENT MONITORING; PHARMACOGENETICS; PREDICTION; PRIORITY JOURNAL; REMISSION; ULCERATIVE COLITIS;

6-MERCAPTOPURINE; AZATHIOPRINE; CHILD; DRUG MONITORING; GUANINE NUCLEOTIDES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; METHYLTHIOINOSINE; METHYLTRANSFERASES; POLYMORPHISM, GENETIC; THIONUCLEOTIDES;

EID: 0344035407     PISSN: 10780998     EISSN: None     Source Type: Journal    
DOI: 10.1097/00054725-200311000-00008     Document Type: Article

References (15)

1. Pearson DC, May GR, Fich GH, et al. Azathioprine and 6-mercaptopurine in Crohn's disease. A meta-analysis. Ann Intern Med. 1995;122:132-142.
2. Markowitz J Grancher K, Kohn N, et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology. 2000:119:895-902.
3. Hawthorne AB, Logan RF, Hawkey, et al. Randomized controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ. 1992:305:20-22.
4. Lennard L. TPMT in the treatment of Crohn's disease with azathioprine. Gut. 2002;51:143-146.
5. Lowry PW, Franklin CL, Weaver AL, et al. Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. Gut. 2001;49:665-670.
6. Lennard L, Van Loon JA, Weinshilboum RM. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther. 1989;46: 149-154.
7. Colombel J-F, Ferrari N, Debuysere H, et al. Genotypic analysis of thiopurine methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology. 2000;118:1025-1030.
8. Connell WR, Kamm MA, Ritchie JK, Lennard-Jones JE. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut. 1993;34:1081-1085.
9. Bergen S, Tugstad HE, Bentdal O, et al. Monitored high-dose azathioprine treatment reduces acute rejection episodes after renal transplantation. Transplantation. 1998;66:334-339.
10. Lilleyman JS, Lennard L. Mercaptopurine metabolism and the risk of relapse in childhood lymphoblastic leukemia, Lancet. 1994;343: 1188-1190.
11. Cuffari C, Theoret Y, Latour S, et al. 6-mercaptopurine metabolism in Crohn's disease correlation with efficacy and toxicity. Gut. 1996;39:401-406.
12. Dubinsky MC, Lamothe S, Yang HY, et al. Parmacogenomics and metabolite measurement ofr 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology. 2000;118:705-713.
13. Dubinsky MC, Yang HY, Hassard PV, et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology. 2002;122:904-915.
14. Sandborn WJ, Tremaine WJ, Wolf DC, et al. Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's diseas. Gastroenterology. 1999;117:527-535.
15. Cuffari C, Hunt S, Bayless T. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimize azathioprine therapy in patients with inflammatory bowel disease. Gut. 2001;48:642-46.